Clinical Outcomes Following Mandatory Switching to an Adalimumab Biosimilar in Patients with Psoriasis: A Real-world Single-centre Experience
- DOI
- 10.2340/actadv.v106.adv-2026-0624
- Published
- 2026-11-02
- Container
- Acta Dermato-Venereologica
- Publisher
- MJS Publishing, Medical Journals Sweden AB
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.2340/actadv.v106.adv-2026-0624,
title = {Clinical Outcomes Following Mandatory Switching to an Adalimumab Biosimilar in Patients with Psoriasis: A Real-world Single-centre Experience},
author = {Mariá Simas D’Aquino and Roberto Moreira Amorim Filho and Gustavo Moreira Amorim},
year = {2026},
journal = {Acta Dermato-Venereologica},
doi = {10.2340/actadv.v106.adv-2026-0624},
url = {https://doi.org/10.2340/actadv.v106.adv-2026-0624}
}RIS
TY - JOUR TI - Clinical Outcomes Following Mandatory Switching to an Adalimumab Biosimilar in Patients with Psoriasis: A Real-world Single-centre Experience AU - Mariá Simas D’Aquino AU - Roberto Moreira Amorim Filho AU - Gustavo Moreira Amorim PY - 2026 JO - Acta Dermato-Venereologica DO - 10.2340/actadv.v106.adv-2026-0624 UR - https://doi.org/10.2340/actadv.v106.adv-2026-0624 ER -
APA
D’Aquino, M. S., Filho, R. M. A., & Amorim, G. M. (2026). Clinical Outcomes Following Mandatory Switching to an Adalimumab Biosimilar in Patients with Psoriasis: A Real-world Single-centre Experience. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v106.adv-2026-0624
Source records
- crossref · retrieved 2026-11-04T09:42:07.415Z